TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30800421

Group type: EXPERIMENTAL
Intervention: ABX464 150-mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ABX464 50-mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30800562

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg once-daily
Number of subjects: 175

Group type: COMPARATOR
Intervention: Ipragliflozin with DPP-4 inhibitor
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 175
Study: 30800637

Group type: EXPERIMENTAL
Intervention: Thyroidectomy (surgery)
Number of subjects: 64
Study: 30801037

Group type: EXPERIMENTAL
Intervention: Tamoxifen combined with amphotericin B and fluconazole
Number of subjects: 0
Study: 30801535

Group type: EXPERIMENTAL
Intervention: Genetic variant rs2910164 (microRNA MIR146A)
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Other genetic variants (CTLA and TLR4)
Number of subjects: 2872

Group type: COMPARATOR
Intervention: 75 common genetic variants
Number of subjects: 2872
Study: 30801647

Group type: EXPERIMENTAL
Intervention: Tomato-soy juice (0, 1, or 2 cans/day; 163 mL/can; 20.6 mg lycopene, 1.2 mg β-carotene/can) for 24 ± 0.7 days
Number of subjects: 47
Study: 30801911

Group type: EXPERIMENTAL
Intervention: BKM120 combined with vemurafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30801984

Group type: EXPERIMENTAL
Intervention: Physical Activity Energy Expenditure (PAEE) in WLM
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Total Daily Energy Expenditure (TDEE) in WLM
Number of subjects: 25
Study: 30801989

Group type: EXPERIMENTAL
Intervention: Daily dietary self-monitoring using a Web-based dietary analysis program
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Self-monitoring frequency
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Time spent self-monitoring
Number of subjects: 142
Study: 30802417

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30802419

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day)
Number of subjects: 199
Study: 30802592

Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair (EVAR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Open surgical repair (OSR)
Number of subjects: 44
Study: 30802998

Group type: EXPERIMENTAL
Intervention: VY-AADC01 (8.3 × 10^10 vg/mL) administered bilaterally with gadoteridol using MRI guidance
Number of subjects: 15
Study: 30803311

Group type: EXPERIMENTAL
Intervention: High-perceived risk/high-perceived control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-perceived risk/low-perceived control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-perceived risk/low-perceived control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-perceived risk/high-perceived control group
Number of subjects: 30
Study: 30803705

Group type: EXPERIMENTAL
Intervention: Miransertib at a dose of 5 mg/m
Number of subjects: 0
Study: 30803948

Group type: EXPERIMENTAL
Intervention: Comprehensive continuous care intervention (CCI)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 349
Study: 30803990

Group type: EXPERIMENTAL
Intervention: Parsaclisib monotherapy (5-45 mg once daily)
Number of subjects: 72
Study: 30803997

Group type: EXPERIMENTAL
Intervention: Non-drug interventions for perinatal depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized treatment approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorporation of patients' preferences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel treatments under investigation
Number of subjects: 0
Study: 30804020

Group type: EXPERIMENTAL
Intervention: Chimeric HER-2 B-cell peptide vaccines emulsified in Montanide ISA 720VG and Nor-MDP adjuvant, administered as three inoculations every 3 weeks.
Number of subjects: 49
Study: 30804030

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using CogState Brief Battery preoperatively and postoperatively at (<3 days), 6 weeks, and 4.5 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delirium assessment using the Confusion Assessment Method (3D-CAM) preoperatively and postoperatively
Number of subjects: 0
Study: 30804739

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0
Study: 30804813

Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Number of subjects: 0
Study: 30805208

Group type: EXPERIMENTAL
Intervention: Internal limiting membrane flap technique
Number of subjects: 9
Study: 30805405

Group type: EXPERIMENTAL
Intervention: 0.2% sodium hyaluronate artificial tears
Number of subjects: 180

Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate artificial tears
Number of subjects: 180
Study: 30805652

Group type: EXPERIMENTAL
Intervention: Older adults with stroke
Number of subjects: 35

Group type: COMPARATOR
Intervention: Older adults without stroke
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Older adults with stroke and poor sleep quality
Number of subjects: 35
Study: 30805768

Group type: EXPERIMENTAL
Intervention: Network analysis of psychosocial risks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prevention of unintended pregnancies and interventions for coping with unplanned pregnancies
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Integrated, multilevel approach to support women during pregnancy
Number of subjects: 200
Study: 30805946

Group type: EXPERIMENTAL
Intervention: Methadone (single oral dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Simplified dosing strategy (model-based simulations)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Methadone (R- and S-enantiomers)
Number of subjects: 31
Study: 30806013

Group type: EXPERIMENTAL
Intervention: Smoking cue reactivity during acute abstinence in the anterior cingulate cortex (ACC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Abstinence-induced change in ACC activation
Number of subjects: 75
Study: 30807351

Group type: EXPERIMENTAL
Intervention: NSTEMI
Number of subjects: 21994

Group type: COMPARATOR
Intervention: STEMI
Number of subjects: 21994
Study: 30807407

Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension (USLS)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Robotic sacrocolpopexy (RSC)
Number of subjects: 186
Study: 30807411

Group type: EXPERIMENTAL
Intervention: Vaginal bowel control system
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 73
Study: 30807645

Group type: EXPERIMENTAL
Intervention: Rogaratinib
Number of subjects: 0
Study: 30808084

Group type: EXPERIMENTAL
Intervention: Statin initiation <24 hours after admission
Number of subjects: 3921

Group type: EXPERIMENTAL
Intervention: Statin initiation <48 hours after admission
Number of subjects: 3921
Study: 30808208

Group type: EXPERIMENTAL
Intervention: Financial incentive-based workplace intervention (24-week duration)
Number of subjects: 225
Study: 30808311

Group type: EXPERIMENTAL
Intervention: Higher income households
Number of subjects: 202
Study: 30808314

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 217
Study: 30808583

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d) with Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 50
Study: 30808770

Group type: EXPERIMENTAL
Intervention: Advanced ultrasound techniques (microbubbles, elastography, ultrafast Doppler, 3D/4D imaging, high-frequency imaging)
Number of subjects: 0
Study: 30809137

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal direct current stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30809184

Group type: EXPERIMENTAL
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 20
Study: 30809591

Group type: EXPERIMENTAL
Intervention: Intrathecal tetanus antitoxin and human intramuscular treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal tetanus antitoxin and equine intramuscular treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure and human intramuscular treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure and equine intramuscular treatment
Number of subjects: 0
Study: 30809725

Group type: EXPERIMENTAL
Intervention: Weight-bearing and resistance exercise training for 3 months
Number of subjects: 33
Study: 30809762

Group type: EXPERIMENTAL
Intervention: Investigational 4 mm × 32G pen needle (BD Nano™ 2nd Gen)
Number of subjects: 150
Study: 30810343

Group type: EXPERIMENTAL
Intervention: Pre-treatment PET parameters (FDG-PET/CT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: HPV negative tumor, N3 lymph node stage
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combination of HPV with PET parameters (MTV, TLG, ZMP)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: PET 2 weeks into treatment
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pre-treatment PET parameters
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Changes in PET parameters from pre- to mid-treatment
Number of subjects: 93
Study: 30810536

Group type: EXPERIMENTAL
Intervention: Enhanced Stepped Care intervention (n=110)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Enhanced Standard Care (n=110)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Enhanced Stepped Care intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Enhanced Standard Care
Number of subjects: 220
Study: 30810593

Group type: EXPERIMENTAL
Intervention: ATTR-FAP patients
Number of subjects: 160
Study: 30811063

Group type: EXPERIMENTAL
Intervention: Cetuximab associated with cisplatin and 5-fluorouracil
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 28
Study: 30811085

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 59
Study: 30811103

Group type: EXPERIMENTAL
Intervention: Low Birth Weight (LBW)
Number of subjects: 2935

Group type: EXPERIMENTAL
Intervention: High Birth Weight (HBW)
Number of subjects: 2935
Study: 30811142

Group type: EXPERIMENTAL
Intervention: Tavaborole 5% topical solution applied once daily to all affected toenails for 48 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tavaborole 5% topical solution applied for the first 28 days to all 10 toenails and ≤2 mm of surrounding skin in a maximal-use subgroup (aged 12 to <17 years)
Number of subjects: 0
Study: 30811285

Group type: EXPERIMENTAL
Intervention: Hu5F9-G4 (5F9) antibody at a priming dose of 1 mg/kg followed by maintenance doses of 3 to 45 mg/kg weekly
Number of subjects: 62
Study: 30811335

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30811388

Group type: EXPERIMENTAL
Intervention: Initial visit stigma assessment
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Follow-up stigma assessment
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Overall change in stigma over 18 months
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Educational level impact on stigma
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Referral to medical care impact on stigma
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Age impact on stigma
Number of subjects: 859
Study: 30811399

Group type: EXPERIMENTAL
Intervention: Machine learning model using LMP, birth weight, twin delivery, maternal height, hypertension in labor, and HIV serostatus.
Number of subjects: 468

Group type: COMPARATOR
Intervention: New Ballard Score (NBS), last menstrual period (LMP), and birth weight used individually.
Number of subjects: 468
Study: 30811475

Group type: EXPERIMENTAL
Intervention: Neutrophil-lymphocyte count ratio (NLCR)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: White blood cell (WBC) count, neutrophil count, lymphocyte count
Number of subjects: 664
Study: 30811537

Group type: EXPERIMENTAL
Intervention: Asfotase alfa 2 mg/kg three times/week or 1 mg/kg six times/week subcutaneously
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Asfotase alfa
Number of subjects: 69
Study: 30811542

Group type: EXPERIMENTAL
Intervention: MC4R mutations identified in children with severe early-onset obesity (8 rare mutations, 2.6%)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Children with MC4R mutations
Number of subjects: 312

Group type: COMPARATOR
Intervention: Children without MC4R mutations
Number of subjects: 312
Study: 30813812

Group type: EXPERIMENTAL
Intervention: Per-vessel FFR in women (0.89±0.10)
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: 3-vessel FFR in women (2.72±0.13)
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Total anatomical and physiologic disease burdens
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Sex influence on total disease burden
Number of subjects: 1136
Study: 30813845

Group type: EXPERIMENTAL
Intervention: 50 g OGTT
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 g OGTT
Number of subjects: 100
Study: 30813927

Group type: EXPERIMENTAL
Intervention: Th2/Th1 ratio
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Persistently increasing Th2/Th1
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 71

Group type: COMPARATOR
Intervention: Critically ill patients without severe sepsis
Number of subjects: 71
Study: 30813942

Group type: EXPERIMENTAL
Intervention: LGE quantification by FWHM
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: LGE quantification by 2-SD
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: LGE quantification by 3-SD
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: LGE-VPS
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: FWHM
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: 2-SD
Number of subjects: 670
Study: 30814321

Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg) plus hydrochlorothiazide (12.5 mg)
Number of subjects: 2361

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg)
Number of subjects: 2361

Group type: EXPERIMENTAL
Intervention: Combination therapy (Candesartan plus Hydrochlorothiazide and Rosuvastatin)
Number of subjects: 2361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2361
Study: 30814647

Group type: EXPERIMENTAL
Intervention: Pathological markers including Neurofilament light chain, phosphorylated heavy chain, 8-oxo-2'-desoxyguanosine, 4-hydroxy-2-nonenal, isoprostane, interleukin-6, ferritin, hepcidin, transferrin
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Composite scores of identified biomarkers in association with established clinical predictors
Number of subjects: 512
Study: 30815001

Group type: EXPERIMENTAL
Intervention: HIV-1 Tat vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30815467

Group type: EXPERIMENTAL
Intervention: Blood and sputum sampling monthly and at exacerbation to detect respiratory infections and eosinophilic inflammation
Number of subjects: 127
Study: 30815468

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)
Number of subjects: 16417

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI)
Number of subjects: 16417

Group type: EXPERIMENTAL
Intervention: Combined FF/VI
Number of subjects: 16417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16417

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and one or more bronchodilators prior to study entry
Number of subjects: 16417
Study: 30815590

Group type: EXPERIMENTAL
Intervention: Family talk intervention (FTI) consisting of six meetings with the family, led by two interventionists.
Number of subjects: 0
Study: 30815589

Group type: EXPERIMENTAL
Intervention: Bariatric surgery before pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obese women without any intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal weight women
Number of subjects: 0
Study: 30815984

Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (wGRS) for CYP2A6 including seven variants
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (wGRS) for CYP2A6
Number of subjects: 1129

Group type: COMPARATOR
Intervention: CYP2A6 gene scoring approaches
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: NMR and C2/N2
Number of subjects: 1129
Study: 30816108

Group type: EXPERIMENTAL
Intervention: Apatinib (VEGFR2 inhibitor)
Number of subjects: 64
Study: 30816569

Group type: EXPERIMENTAL
Intervention: Getting Research into Practice model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical audits and situation analysis
Number of subjects: 0
Study: 30816625

Group type: EXPERIMENTAL
Intervention: Alpha IMS device
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alpha AMS device
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall (both devices)
Number of subjects: 35
Study: 30816809

Group type: EXPERIMENTAL
Intervention: Real-world therapies chosen for multiple myeloma patients
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: Real-world safety and healthcare resource utilization
Number of subjects: 4200
Study: 30816849

Group type: EXPERIMENTAL
Intervention: Digital intervention (AI-powered biofeedback system, remote monitoring)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional rehabilitation (face-to-face sessions)
Number of subjects: 59
Study: 30817463

Group type: EXPERIMENTAL
Intervention: 24-h dietary recalls
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24-h urine collections
Number of subjects: 0
Study: 30819010

Group type: EXPERIMENTAL
Intervention: Youth Mentor Dietary Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30819173

Group type: EXPERIMENTAL
Intervention: Observation of Mother-Child Interaction (OMCI) measure during a 5-min picture book activity at 24 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation of Mother-Child Interaction (OMCI) measure controlling for HOME score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30819182

Group type: EXPERIMENTAL
Intervention: Complete revascularization (CR, rSS = 0) in OSA patients
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Incomplete revascularization (ICR, rSS > 0) in non-OSA patients
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Incomplete revascularization (ICR) in OSA patients
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) group
Number of subjects: 752
Study: 30819210

Group type: EXPERIMENTAL
Intervention: Sotagliflozin (as monotherapy or add-on therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotagliflozin (in adults with T1D treated with continuous subcutaneous insulin infusion or multiple daily insulin injections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 0
Study: 30819368

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30819549

Group type: EXPERIMENTAL
Intervention: Single sub-anesthetic dose of ketamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low baseline FC between PFC and sgACC
Number of subjects: 24
Study: 30819704

Group type: EXPERIMENTAL
Intervention: Patient-initiated screening
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Health provider-initiated follow-up screening
Number of subjects: 15
Study: 30819913

Group type: EXPERIMENTAL
Intervention: Platelet transfusions at a threshold platelet count of 50x10^9/L
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platelet transfusions
Number of subjects: 0
Study: 30820338

Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion (TCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bolus administration of propofol
Number of subjects: 0
Study: 30820341

Group type: EXPERIMENTAL
Intervention: Toolkit for Optimal Recovery (TOR) delivered via secure live video
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 54
Study: 30809591

Group type: EXPERIMENTAL
Intervention: Intrathecal tetanus antitoxin
Number of subjects: 0
Study: 30820530

Group type: EXPERIMENTAL
Intervention: Adalimumab therapy
Number of subjects: 28
Study: 30820841

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: SQLS Motivation subscale
Number of subjects: 304

Group type: COMPARATOR
Intervention: EQ-5D
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: SQLS
Number of subjects: 304
Study: 30821692

Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral intervention based on social cognitive theory (SCT) with video calls from a behavioral coach for increasing physical activity in MS.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in detail, but monitoring plans and strategies are consistent across groups.
Number of subjects: 0
Study: 30821848

Group type: EXPERIMENTAL
Intervention: ipilimumab treatment
Number of subjects: 56
Study: 30822272

Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg, once daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg, twice daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg, once daily
Number of subjects: 300
Study: 30822389

Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise program (twice a week for 8 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clinical tests (DMC scale, CTTD, PLE test)
Number of subjects: 64
Study: 30822515

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 0
Study: 30822559

Group type: EXPERIMENTAL
Intervention: Serum PFASs (specifically perfluorooctanesulfonate and perfluoroundecanoic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group (Comparison)
Number of subjects: 0
Study: 30823880

Group type: EXPERIMENTAL
Intervention: SF-36 Health Status Questionnaire (version 2)
Number of subjects: 258
Study: 30823897

Group type: EXPERIMENTAL
Intervention: FFR-guided complete revascularization (CR)
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Culprit-only revascularization (COR)
Number of subjects: 1631
Study: 30824206

Group type: COMPARATOR
Intervention: Photobiomodulation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study: 30824558

Group type: EXPERIMENTAL
Intervention: CoRisk score (including copeptin levels, age, NIH Stroke Scale, and recanalization therapy)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: CoRisk score without copeptin
Number of subjects: 1102